Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma
| Autor: | Steven J. Cohen, Crystal S. Denlinger, C. McAleer, R. Katherine Alpaugh, Karen Ruth, Catherine A. Thrash-Bingham, Benjamin P. Negin, Patricia Fittipaldi, Neal J. Meropol, Michael J. Hall, Igor Astsaturov, Efrat Dotan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Endocrinology Diabetes and Metabolism Pilot Projects Tumor cells Adenocarcinoma Article 03 medical and health sciences 0302 clinical medicine Endocrinology Circulating tumor cell Pancreatic cancer Internal medicine Metastatic pancreatic cancer Biomarkers Tumor Internal Medicine medicine Humans In patient Hepatology business.industry Middle Aged Metastatic Pancreatic Adenocarcinoma Neoplastic Cells Circulating Prognosis medicine.disease Pancreatic Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Female CA19-9 business |
| Zdroj: | Pancreas. 45:1131-1135 |
| ISSN: | 0885-3177 |
| DOI: | 10.1097/mpa.0000000000000619 |
| Popis: | Development of targeted therapies for pancreatic cancer could be enhanced by a reliable method for noninvasive tumor cell assessment. In this pilot study, we isolated and phenotypically characterized circulating tumor cells (CTCs) from patients with metastatic pancreatic cancer and explored their relationship to clinical outcome.Peripheral blood from 50 patients was collected at treatment initiation and first disease evaluation for CTC enumeration and phenotyping by CellSearch® system. Expression of human mucin 1 (MUC-1) was performed.Forty-eight and 37 patients had evaluable samples at baseline and first disease evaluation, respectively. The cohort was 62% male, with a median age of 63 years. At least 1 CTC per 7.5 mL was detected in 23 patients (48%) pretreatment and 11 patients (30%) at first disease evaluation. No difference was seen in overall survival between patients with 1 or more CTCs versus no CTC at baseline (P = 0.14). Patients with MUC-1 expressing CTC (n = 10) had shorter median overall survival compared with those with MUC-1 negative CTC (n = 13; 2.7 vs 9.6 m; P = 0.044).Circulating tumor cell enumeration and phenotypic characterization from metastatic pancreatic cancer patients are feasible. No correlation was found between CTC isolation and survival. However, the presence of MUC-1 expressing CTC demonstrated a trend toward inferior survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|